Meta Pixel

News and Announcements

Unlocking Investor Trust: Anticipate Questions and Build Trust with FAQs

  • Published May 16, 2023 11:00PM UTC
  • Publisher Wholesale Investor
  • Categories Capital Raising Tips

As a startup founder raising capital, it’s essential to make the investment process as straightforward as possible for your potential investors. In this video, you will learn that one way to demonstrate a professional approach is to anticipate and answer potential investors’ questions before they ask them.

By providing frequently asked questions (FAQs) on your website or in your investment materials, you can give investors the information they need to make an informed decision about investing in your company. This not only helps build trust and credibility but can also save time during the due diligence process, as investors will already have answers to many of their questions.

Here, we provide several examples of common investor questions and suggest how founders can address them in their FAQs. From inquiries about the size of the market to questions about the company’s management team, the FAQs can cover a wide range of topics. It is recommended to update the FAQs regularly to reflect changes in the business or in response to feedback from investors.

YouTube player

Overall, it is essential to be proactive in addressing investors’ questions and providing clear and concise information to help potential investors make informed decisions. By anticipating and answering common questions through a well-crafted FAQ, startup founders can demonstrate their professionalism and improve their chances of successfully raising capital.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now